Market Overview:
The global tyrosine protein kinase lyn market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of cancer, increasing R&D investments for novel therapies, and growing demand for targeted therapies. Based on type, the global tyrosine protein kinase lyn market is segmented into tolimidone, rebastinib Tosylate, nintedanib, masitinib and others. Based on application, the global tyrosine protein kinase lyn market is segmented into in-patient and out-patient. Geographically, the global tyrosine protein kinase lyn market is segmented into North America (U.S., Canada), Latin America (Mexico), Europe (Germany France U.K.), Asia Pacific (China Japan India) and Middle East & Africa (Saudi Arabia UAE).
Product Definition:
Tyrosine protein kinase Lyn is an enzyme that catalyzes the transfer of a phosphate group from ATP to the tyrosine residue of a target protein. Lyn is important for signaling pathways that regulate cell growth, differentiation, and survival.
Tolimidone:
Tolimidone is an organic compound with a pyrrolizidine ring structure. It is also known as 1-methyl-4-piperidone. Tolimidone has been reported to have antihypertensive, immunosuppressive and antimalarial properties which may be due to its structural similarity with quinoline or because of unspecific activity against vascular smooth muscle cells (VSMC).
Rebastinib Tosylate:
Rebastinib tosylate is a drug used in the treatment of chronic myelogenous leukemia. It is an injectable form of the drug, which acts as a tyrosine protein kinase (PKK) inhibitor. The U.S. FDA-approved rebastinib tosylate for use as single agent and in combination with other drugs for treatment of patients with chronic myelogenous leukemia (CML).
Application Insights:
In-patient treatment accounted for the largest revenue share in 2016. The segment is expected to witness significant growth during the forecast period due to increasing incidence of cancer and other life-threatening diseases. Tyrosine protein kinase lysine (TKL) inhibitors are used for treating a variety of cancers, including lung, breast, liver & biliary system, colorectal cancer and head & neck cancer.
The out-patient treatment segment is expected to witness fastest growth during the forecast period owing to rising awareness about TKIs among patients with different types of cancers across the globe. Increasing number of clinical trials that have proven TKI drugs as an effective alternative therapy for various types of malignant tumors are further anticipated to boost market growth over the coming years.
Regional Analysis:
North America accounted for the largest share of revenue in 2017. The presence of key players, favorable reimbursement scenario, and high awareness levels among patients are some factors responsible for its dominance. In addition, the availability of effective treatment options is expected to drive regional market growth over the forecast period.
Asia Pacific is estimated to be one of the fastest-growing regions during the forecast period owing to increasing number of product launches coupled with growing target population base in emerging countries such as China and India. Moreover, rising healthcare expenditure by governments along with improving healthcare infrastructure will boost market growth over this period. Japan has been observed as a lucrative country for global tyrosine protein kinase lys due to various factors such as favorable reimbursement scenario and rapidly aging population that requires chronic therapy management (Kawasaki disease).
Growth Factors:
- Increasing prevalence of cancer and other diseases that can be treated with Tyrosine Protein Kinase Lyn inhibitors
- Growing demand for targeted cancer therapies
- Rising number of clinical trials for Tyrosine Protein Kinase Lyn inhibitors
- increasing investment in research and development by pharmaceutical companies to develop new drugs 5. Technological advancements that will help improve the efficacy and safety of Tyrosine Protein Kinase Lyn inhibitors
Scope Of The Report
Report Attributes
Report Details
Report Title
Tyrosine Protein Kinase Lyn Market Research Report
By Type
Tolimidone, Rebastinib Tosylate, Nintedanib, Masitinib, Others
By Application
In-Patient, Out-Patient
By Companies
AB Science SA, Boehringer Ingelheim GmbH, Deciphera Pharmaceuticals, LLC, Pfizer Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Tyrosine Protein Kinase Lyn Market Report Segments:
The global Tyrosine Protein Kinase Lyn market is segmented on the basis of:
Types
Tolimidone, Rebastinib Tosylate, Nintedanib, Masitinib, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
In-Patient, Out-Patient
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AB Science SA
- Boehringer Ingelheim GmbH
- Deciphera Pharmaceuticals, LLC
- Pfizer Inc.
Highlights of The Tyrosine Protein Kinase Lyn Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tolimidone
- Rebastinib Tosylate
- Nintedanib
- Masitinib
- Others
- By Application:
- In-Patient
- Out-Patient
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tyrosine Protein Kinase Lyn Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tyrosine Protein Kinase Lyn is an enzyme that catalyzes the transfer of a phosphate group from ATP to tyrosine. This results in the activation of protein kinases and the initiation of cellular responses.
Some of the major companies in the tyrosine protein kinase lyn market are AB Science SA, Boehringer Ingelheim GmbH, Deciphera Pharmaceuticals, LLC, Pfizer Inc..
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Tyrosine Protein Kinase Lyn Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Tyrosine Protein Kinase Lyn Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Tyrosine Protein Kinase Lyn Market - Supply Chain
4.5. Global Tyrosine Protein Kinase Lyn Market Forecast
4.5.1. Tyrosine Protein Kinase Lyn Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Tyrosine Protein Kinase Lyn Market Size (000 Units) and Y-o-Y Growth
4.5.3. Tyrosine Protein Kinase Lyn Market Absolute $ Opportunity
5. Global Tyrosine Protein Kinase Lyn Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Type
5.3.1. Tolimidone
5.3.2. Rebastinib Tosylate
5.3.3. Nintedanib
5.3.4. Masitinib
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Tyrosine Protein Kinase Lyn Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Application
6.3.1. In-Patient
6.3.2. Out-Patient
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Tyrosine Protein Kinase Lyn Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Tyrosine Protein Kinase Lyn Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Tyrosine Protein Kinase Lyn Demand Share Forecast, 2019-2026
9. North America Tyrosine Protein Kinase Lyn Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Application
9.4.1. In-Patient
9.4.2. Out-Patient
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Type
9.7.1. Tolimidone
9.7.2. Rebastinib Tosylate
9.7.3. Nintedanib
9.7.4. Masitinib
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Tyrosine Protein Kinase Lyn Demand Share Forecast, 2019-2026
10. Latin America Tyrosine Protein Kinase Lyn Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Application
10.4.1. In-Patient
10.4.2. Out-Patient
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Type
10.7.1. Tolimidone
10.7.2. Rebastinib Tosylate
10.7.3. Nintedanib
10.7.4. Masitinib
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Tyrosine Protein Kinase Lyn Demand Share Forecast, 2019-2026
11. Europe Tyrosine Protein Kinase Lyn Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Application
11.4.1. In-Patient
11.4.2. Out-Patient
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Type
11.7.1. Tolimidone
11.7.2. Rebastinib Tosylate
11.7.3. Nintedanib
11.7.4. Masitinib
11.7.5. Others
11.8. Bais Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Tyrosine Protein Kinase Lyn Demand Share, 2019-2026
12. Asia Pacific Tyrosine Protein Kinase Lyn Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Application
12.4.1. In-Patient
12.4.2. Out-Patient
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Type
12.7.1. Tolimidone
12.7.2. Rebastinib Tosylate
12.7.3. Nintedanib
12.7.4. Masitinib
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Tyrosine Protein Kinase Lyn Demand Share, 2019-2026
13. Middle East & Africa Tyrosine Protein Kinase Lyn Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Application
13.4.1. In-Patient
13.4.2. Out-Patient
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Tyrosine Protein Kinase Lyn Market Size and Volume Forecast by Type
13.7.1. Tolimidone
13.7.2. Rebastinib Tosylate
13.7.3. Nintedanib
13.7.4. Masitinib
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Tyrosine Protein Kinase Lyn Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Tyrosine Protein Kinase Lyn Market: Market Share Analysis
14.2. Tyrosine Protein Kinase Lyn Distributors and Customers
14.3. Tyrosine Protein Kinase Lyn Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AB Science SA
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Boehringer Ingelheim GmbH
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Deciphera Pharmaceuticals, LLC
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer Inc.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
